This company is no longer active
EIGR.Q Stock Overview
A commercial-stage biopharmaceutical company, focuses on the development of therapies for hepatitis delta virus (HDV) and other serious diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Eiger BioPharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$8.50 |
| 52 Week High | US$16.00 |
| 52 Week Low | US$1.10 |
| Beta | 2.78 |
| 1 Month Change | -15.00% |
| 3 Month Change | -24.11% |
| 1 Year Change | -5.59% |
| 3 Year Change | -95.66% |
| 5 Year Change | -97.13% |
| Change since IPO | -98.22% |
Recent News & Updates
Recent updates
Eiger BioPharmaceuticals, Inc.'s (NASDAQ:EIGR) 28% Dip In Price Shows Sentiment Is Matching Revenues
Apr 01
The Market Doesn't Like What It Sees From Eiger BioPharmaceuticals, Inc.'s (NASDAQ:EIGR) Revenues Yet As Shares Tumble 26%
Jan 04Analysts Have Just Cut Their Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) Revenue Estimates By 22%
Dec 20Analyst Forecasts For Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) Are Surging Higher
Nov 09Rock star Growth Puts Eiger BioPharmaceuticals (NASDAQ:EIGR) In A Position To Use Debt
Oct 06Eiger sheds ~20% on abandonment of EUA request for COVID therapy
Oct 05Eiger falls 21% amid uncertainty over regulatory path for COVID-19 therapy
Sep 06Eiger BioPharmaceuticals: Undervalued Biotech With End Of 2022 Catalyst
Jul 26European Commission approves Eiger BioPharmaceuticals' progeria therapy Zokinvy
Jul 20Shareholder Returns
| EIGR.Q | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0% | -1.3% | -1.7% |
| 1Y | -5.6% | -8.9% | 5.6% |
Return vs Industry: EIGR.Q underperformed the US Biotechs industry which returned 21.7% over the past year.
Return vs Market: EIGR.Q underperformed the US Market which returned 33.4% over the past year.
Price Volatility
| EIGR.Q volatility | |
|---|---|
| EIGR.Q Average Weekly Movement | 12.9% |
| Biotechs Industry Average Movement | 10.6% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 16.9% |
| 10% least volatile stocks in US Market | 3.3% |
Stable Share Price: EIGR.Q's share price has been volatile over the past 3 months.
Volatility Over Time: EIGR.Q's weekly volatility has decreased from 39% to 13% over the past year, but is still higher than 75% of US stocks.
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 25 | David Apelian | www.eigerbio.com |
Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development of therapies for hepatitis delta virus (HDV) and other serious diseases. The company offers Zokinvy for the treatment of Hutchinson-Gilford progeria syndrome and Processing-Deficient Progeroid Laminopathies. Its product candidates include Lonafarnib, an orally available, farnesylation inhibitor, which has completed Phase 3 clinical trials for HDV infection; Peginterferon Lambda (lambda), which is in clinical development for HDV; lambda, that is in phase II and III investigator studies of mild and moderate COVID-19; and Avexitide, which is in Phase II for the treatment of congenital hyperinsulinism and post-bariatric hypoglycemia.
Eiger BioPharmaceuticals, Inc. Fundamentals Summary
| EIGR.Q fundamental statistics | |
|---|---|
| Market cap | US$12.59m |
| Earnings (TTM) | -US$74.96m |
| Revenue (TTM) | US$15.77m |
0.8x
P/S Ratio-0.2x
P/E RatioIs EIGR.Q overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| EIGR.Q income statement (TTM) | |
|---|---|
| Revenue | US$15.77m |
| Cost of Revenue | US$24.00k |
| Gross Profit | US$15.75m |
| Other Expenses | US$90.71m |
| Earnings | -US$74.96m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -50.62 |
| Gross Margin | 99.85% |
| Net Profit Margin | -475.26% |
| Debt/Equity Ratio | -284.4% |
How did EIGR.Q perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/10/02 20:52 |
| End of Day Share Price | 2024/10/01 00:00 |
| Earnings | 2023/12/31 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Eiger BioPharmaceuticals, Inc. is covered by 11 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Madhu Kumar | Baird |
| Brian Skorney | Baird |
| Madhu Kumar | B. Riley Securities, Inc. |